Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Lipocine Inc (LPCN)

Lipocine Inc (LPCN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Lipocine Inc 675 ARAPEEN DRIVE SUITE 202 SALT LAKE CITY UT 84108 USA

www.lipocine.com P: 801-994-7383 F: 801-994-7388

Description:

Lipocine, Inc. is a specialty pharmaceutical company. It develops pharmaceutical products for use in men's and women's health. The Company's lead product candidate, LPCN 1021, is in Phase 3 and is targeted to treat symptoms of low testosterone for men in need of testosterone replacement therapy. Its additional pipeline candidates include LPCN 1111, a next generation oral testosterone therapy product, and LPCN 1107, indicated for the prevention of preterm birth and is currently in Phase 1. Lipocine Inc. is headquartered in Salt Lake City, Utah.

Key Statistics

Overview:

Market Capitalization, $K 23,602
Enterprise Value, $K 18,832
Shares Outstanding, K 5,316
Annual Sales, $ -2,850 K
Annual Net Income, $ -16,350 K
Last Quarter Sales, $ 220 K
Last Quarter Net Income, $ -2,280 K
EBIT, $ -17,930 K
EBITDA, $ -18,850 K
60-Month Beta 1.05
% of Insider Shareholders 5.00%
% of Institutional Shareholders 9.11%
Float, K 5,050
% Float 95.00%
Short Volume Ratio 0.30

Growth:

1-Year Return -6.35%
3-Year Return -81.48%
5-Year Return -85.57%
5-Year Revenue Growth -762.79%
5-Year Earnings Growth 66.42%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.42 on 03/07/24
Latest Earnings Date 05/09/24
Earnings Per Share ttm -3.05
EPS Growth vs. Prev Qtr 66.93%
EPS Growth vs. Prev Year 17.68%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-17 on 05/12/23

LPCN Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -63.28%
Return-on-Assets % -58.27%
Profit Margin % 573.68%
Debt/Equity 0.00
Price/Sales -8.28
Price/Cash Flow N/A
Price/Book 1.32
Book Value/Share 3.83
Interest Coverage -2.34
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar